◎ Sugi Atlas

Atlas / Drug / Lithium

Lithium

drug
On this page

Also known as LI

Summary

Lithium (CHEMBL1201333) is a phase-3 clinical-stage small molecule (ATC N05AN01) targeting IMPA1 and GSK3B; indicated across 2 conditions including bipolar disorder and psychotic disorder.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • ATC class: N05AN01
  • Targets: 2 (IMPA1, GSK3B)
  • Indications: 2 conditions
  • Clinical trials: 118
  • Chemistry: Li

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201333
NameLithium
TypeSmall molecule
Max phase3
ChEBICHEBI:30145
ATCN05AN01
Molecular formulaLi
InChIKeyWHXSMMKQMYFTQS-UHFFFAOYSA-N

SMILES: [Li]

Also known as: LI, Lithium, lithium, LITHIUM

Patent coverage: 327 distinct patent families (537 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
IMPA1IMPase 1Inhibition3.50.2%P29218
GSK3Bglycogen synthase kinase 3 betaInhibition2.62.5%P49841

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): IMPA1, GSK3B.

Top Reactome pathways

29 total, by targets touching each:

PathwayTargetsGenes
Metabolism1IMPA1
Inositol phosphate metabolism1IMPA1
Synthesis of IP2, IP, and Ins in the cytosol1IMPA1
Degradation of beta-catenin by the destruction complex1GSK3B
Beta-catenin phosphorylation cascade1GSK3B
AKT phosphorylates targets in the cytosol1GSK3B
Regulation of HSF1-mediated heat shock response1GSK3B
CRMPs in Sema3A signaling1GSK3B
Disassembly of the destruction complex and recruitment of AXIN to the membrane1GSK3B
B-WICH complex positively regulates rRNA expression1GSK3B
Signaling by GSK3beta mutants1GSK3B
CTNNB1 S33 mutants aren’t phosphorylated1GSK3B
CTNNB1 S37 mutants aren’t phosphorylated1GSK3B
CTNNB1 S45 mutants aren’t phosphorylated1GSK3B
CTNNB1 T41 mutants aren’t phosphorylated1GSK3B
APC truncation mutants have impaired AXIN binding1GSK3B
AXIN missense mutants destabilize the destruction complex1GSK3B
Truncations of AMER1 destabilize the destruction complex1GSK3B
Degradation of GLI2 by the proteasome1GSK3B
GLI3 is processed to GLI3R by the proteasome1GSK3B
Constitutive Signaling by AKT1 E17K in Cancer1GSK3B
Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A1GSK3B
Ubiquitin-dependent degradation of Cyclin D1GSK3B
Regulation of RUNX2 expression and activity1GSK3B
Maturation of nucleoprotein1GSK3B
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L21GSK3B
Transcriptional and post-translational regulation of MITF-M expression and activity1GSK3B
GSK3B-mediated proteasomal degradation of PD-L1(CD274)1GSK3B

Dominant GO biological processes

GO termTargets
inositol metabolic process1
inositol biosynthetic process1
phosphatidylinositol biosynthetic process1
phosphate-containing compound metabolic process1
signal transduction1
phosphatidylinositol phosphate biosynthetic process1
epithelial to mesenchymal transition1
positive regulation of cell-matrix adhesion1
heart valve development1
glycogen metabolic process1
protein phosphorylation1
ER overload response1
mitochondrion organization1
circadian rhythm1
insulin receptor signaling pathway1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
bipolar disorder3MONDO:0004985MONDO:0004985
psychotic disorder3MONDO:0005485EFO:0005407

Clinical trials

Total trials: 118.

Phase distribution

PhaseTrials
PHASE440
Not specified30
PHASE319
PHASE29
PHASE19
PHASE1/PHASE28
PHASE2/PHASE32
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05913947PHASE4RECRUITINGLithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)
NCT00021528PHASE4COMPLETEDSequenced Treatment Alternatives to Relieve Depression (STAR*D)
NCT00044616PHASE4COMPLETEDRelapse Prevention for Bipolar Type-II Disorder
NCT00045916PHASE4COMPLETEDOptimizing Electroconvulsive Therapy for Depression
NCT00048802PHASE4COMPLETEDTreatment and Outcome of Early Onset Bipolar Disorder
NCT00202293PHASE4COMPLETEDComparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
NCT00254488PHASE4COMPLETEDTreatment of Bipolar Mania in Older Adults
NCT00457054PHASE4COMPLETEDFunctional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania
NCT00596622PHASE4COMPLETEDFMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
NCT00608075PHASE4UNKNOWNNeurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder
NCT00627887PHASE4COMPLETEDRandomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression
NCT00672490PHASE4COMPLETEDQuetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder
NCT00926835PHASE4TERMINATEDEffect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients
NCT00927550PHASE4UNKNOWNLithium and Standard Therapy in Resistant Depression
NCT00931723PHASE4COMPLETEDAdult Bipolar Mania
NCT00961961PHASE4COMPLETEDPrevention of Relapse & Recurrence of Bipolar Depression
NCT00974155PHASE4COMPLETEDThe Early Medication Change (EMC) Trial
NCT01028508PHASE4COMPLETEDProlonging Remission in Depressed Elderly (PRIDE)
NCT01075126PHASE4WITHDRAWNSafety Study of Depakote Versus Lithium in African Americans With Bipolar Disorder
NCT01134731PHASE4COMPLETEDPaliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation
NCT01191918PHASE4COMPLETEDThe Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania
NCT01254721PHASE4TERMINATEDA Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study
NCT01331304PHASE4COMPLETEDComparative Effectiveness Study for Bipolar Disorder
NCT01348282PHASE4COMPLETEDEfficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study
NCT01416220PHASE4WITHDRAWNLithium Versus Paroxetine in Major Depression
NCT01526148PHASE4TERMINATEDGao Bipolar Spectrum Lithium/Quetiapine Study
NCT01543724PHASE4WITHDRAWNNeural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder
NCT01588457PHASE4COMPLETEDSequential Multiple Assignment Treatment for Bipolar Disorder
NCT01710163PHASE4UNKNOWNPotentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients
NCT01893229PHASE4UNKNOWNComparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania
NCT01919892PHASE4COMPLETEDLongitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium
NCT01938859PHASE4UNKNOWNAlgorithm Guided Treatment Strategies for Bipolar Depression
NCT02287259PHASE4COMPLETEDOlanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study)
NCT02870283PHASE4COMPLETEDCost- Effectiveness and Quality of Life Assessment in Mood Disorder
NCT02901249PHASE4COMPLETEDCost- Effectiveness and Quality of Life Assessment in Major Depression Disorder
NCT02909504PHASE4TERMINATEDGao NARASD Lithium Study
NCT02960763PHASE4COMPLETEDOptimizing Outcomes of Treatment-Resistant Depression in Older Adults
NCT03004521PHASE4UNKNOWNLithium Versus Quetiapine in Treatment Resistant Depression
NCT03219008PHASE4UNKNOWNMulti-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics
NCT05531591PHASE4COMPLETEDRCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

58 molecules share ≥1 primary target. Top 58 by shared-target count:

MoleculeSourceStatusShared targets
ABEMACICLIBChEMBLPhase 4 (approved)GSK3B
ENCORAFENIBChEMBLPhase 4 (approved)GSK3B
EPALRESTATChEMBLPhase 4 (approved)GSK3B
MIDOSTAURINChEMBLPhase 4 (approved)GSK3B
NICLOSAMIDEChEMBLPhase 4 (approved)GSK3B
NINTEDANIBChEMBLPhase 4 (approved)GSK3B
PALBOCICLIBChEMBLPhase 4 (approved)GSK3B
SORAFENIBChEMBLPhase 4 (approved)GSK3B
ALVOCIDIBChEMBLPhase 3GSK3B
CURCUMINChEMBLPhase 3GSK3B
DEFACTINIBChEMBLPhase 3GSK3B
DINACICLIBChEMBLPhase 3GSK3B
DOVITINIBChEMBLPhase 3GSK3B
ENZASTAURINChEMBLPhase 3GSK3B
EPIGALOCATECHIN GALLATEChEMBLPhase 3GSK3B
HESPERIDINChEMBLPhase 3GSK3B
LESTAURTINIBChEMBLPhase 3GSK3B
LORECIVIVINTChEMBLPhase 3GSK3B
PIMODIVIRChEMBLPhase 3GSK3B
QUERCETINChEMBLPhase 3GSK3B
RUBOXISTAURINChEMBLPhase 3GSK3B
THIAZOLIDINEDIONEChEMBLPhase 3GSK3B
AT-7519ChEMBLPhase 2GSK3B
AT-9283ChEMBLPhase 2GSK3B
BERZOSERTIBChEMBLPhase 2GSK3B
BMS-754807ChEMBLPhase 2GSK3B
BMS-919373ChEMBLPhase 2GSK3B
CC-401ChEMBLPhase 2GSK3B
DALMELITINIBChEMBLPhase 2GSK3B
DAROVASERTIBChEMBLPhase 2GSK3B
DORAMAPIMODChEMBLPhase 2GSK3B
ELLAGIC ACIDChEMBLPhase 2GSK3B
ELRAGLUSIBChEMBLPhase 2GSK3B
FISETINChEMBLPhase 2GSK3B
INDIRUBINChEMBLPhase 2GSK3B
LUTEOLINChEMBLPhase 2GSK3B
LY-2090314ChEMBLPhase 2GSK3B
R-406ChEMBLPhase 2GSK3B
RAVOXERTINIBChEMBLPhase 2GSK3B
RG-547ChEMBLPhase 2GSK3B
SELICICLIBChEMBLPhase 2GSK3B
SILMITASERTIBChEMBLPhase 2GSK3B
SOTRASTAURINChEMBLPhase 2GSK3B
TEGTOCICLIBChEMBLPhase 2GSK3B
TIDEGLUSIBChEMBLPhase 2GSK3B
ZEMIRCICLIBChEMBLPhase 2GSK3B
ZOTIRACICLIBChEMBLPhase 2GSK3B
AfatinibPubChemApprovedGSK3B
BelzutifanPubChemApprovedGSK3B
BinimetinibPubChemApprovedGSK3B
CrizotinibPubChemApprovedGSK3B
dacomitinibPubChemApprovedGSK3B
FostamatinibPubChemApprovedGSK3B
IdelalisibPubChemApprovedGSK3B
PazopanibPubChemApprovedGSK3B
regorafenibPubChemApprovedGSK3B
SelumetinibPubChemApprovedGSK3B
TrametinibPubChemApprovedGSK3B

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot